Does dimethicone increase the efficacy of antacids in the treatment of reflux oesophagitis? Introduction The composition of antacid mixtures varies greatly, not only in the nature of the antacid components but also in the incorporation of additives which are claimed to increase their efficacy. The commonest of these additives is dimethicone, a silicone polymer which is believed to have antiflatulent1' 2 and mucosal protective properties3'4. However, there have been no previously reported studies of the value of this additive to an antacid mixture in the treatment of reflux oesophagitis.
This study was designed to assess the effect of the addition of dimethicone to an antacid gel in the treatment of reflux oesophagitis in a double-blind controlled trial. 0141-0768/86/ 010584-04/$02.00/0 i 1986
The Royal Society of Medicine Patients and methods Forty-five adult patients were recruited into the study from a general gastroenterological outpatient clinic. Those patients who had received dimethiconecontaining treatment in the previous six weeks were excluded and those whose symptomatic gastrooesophageal reflux was not controlled on their current medication were included after a two-week washout period. The study was approved by the Ethical Committee of the University Hospital, Nottingham, and valid informed consent was obtained from each patient.
Symptoms of gastro-oesophageal reflux comprising pain, regurgitation and flatulence were graded from 0 to 4 according to frequency and severity (Table  1 ). Fibreoptic upper gastrointestinal endoscopy and oesophageal biopsy were performed by an experienced endoscopist and the severity of oesophagitis, ulceration and histological changes were individually graded from 0 to 4 (Tables 2 and 3) .
Patients with other upper gastrointestinal pathology were excluded from this study.
Lower oesophageal sphincter pressure was measured using a triple-lumen tube (external diameter 3.5 mm) perfused at a rate of 0.8 ml/min from greased glass syringes driven by an electrically powered syringe pump. The maximum rate of pressure rise in this system was 800 mmHg when the recording orifices were occluded, and the pressure rose to 60 mmHg in 0.2 seconds. Following the measurement of sphincter pressure, the pattern of oesophageal motility was assessed. Oesophageal motility was regarded as abnormal if frequent secondary peristaltic waves were present at rest or if non-propulsive contractions were present at rest or after a swallow.
An oesophageal acid perfusion test was performed using concurrent motility recording. A control infusion of 0.9% NaCl solution was infused at a rate of 10 ml/min. If there was no pain, the infusate was changed without the patient's knowledge to 0.1 M HCI, infused at. the same rate. The time from the Less than once a day and clearly precipitated, e.g. by stooping or lifting 2 Less than once a day with no precipitating factors 3 More than once a day with or without precipitating factors 4 Frequent or persistent regurgitation Flatulence 0 None 1 Once a day or less - 2 More than once a day 3 After every meal 4 Persistent and frequent with social embarrassment Oedema and friability of the mucosa involving less than 50% of the circumference and restricted to the lower 2 cm of the oesophagus 2
As 1, but involving most of the circumference of the oesophagus 3
As 1 but extending above the lower 2 cm of the oesophagus 4
As 3, but involving more than 50% of the oesophagus Ulceration 0 Nil 1 Small superficial ulcers surrounded by erythema, maximum of three in number and restricted to the lower 2 cm of the oesophagus 2
As 1, but more than 3 ulcers 3 Superficial ulceration, but extending above the lower 2 cm of the oesophagus 4
Chronic peptic ulceration of the oesophagus Table 3 . Grading of histological changes on oesophageal biopsy in patients with reflux oesophagitis 0 Normal 1
Occasional polymorphonuclear leukocytes around submucosal papillae 2 As 1, but with scattered polymorphs in the epithelium between papillae 3
Polymorphs conspicuous throughout fields of the biopsy 4 Evidence of ulceration to alter tobacco or alcohol consumption and no other measures to avoid or reduce gastro-oesophageal reflux were taken. Patients were requested to fill in diary cards, recording the frequency of pain and regurgitation during daytime and night-time periods. Patients were reviewed in the clinic after four and eight weeks' treatment, when symptoms were again graded. They were also asked for a subjective assessment as to whether each symptom had improved or deteriorated. On completion of the trial at eight weeks, endoscopy, oesophageal biopsy, oesophageal motility studies and oesophageal acid perfusion studies were repeated.
If a patient was withdrawn from the study, the next available subject entered into the trial was allocated the same treatment regimen as the withdrawal. Extra trial packs for this eventuality were held by the pharmacy, ensuring the continued 'blindness' of the trial.
Assessment ofdifferences between treatments
In addition to assessing the median scores for each symptom grade and for the severity of oesophagitis, a combined overall assessment was derived for symptoms and severity of oesophagitis separately. The overall symptomatic assessment was derived by subtracting the score for each symptom at week 8 from that at week 0. A positive value indicated improvement (and was assigned + 1) while a negative value indicated worsening of that symptom (and was assigned -1). An overall symptom assessment for the eight-week study period was thus calculated and ranged from +3 to -3.
The severity of oesophagitis was assessed by several methods, and the combined assessment score was derived by similarly treating the degrees of oesophagitis and ulceration at endoscopy, the grading of the oesophageal biopsies and the time to the onset of pain with acid perfusion. A score for improvement or deterioration in oesophagitis ranging from + 4 to -4 was thus derived. commencement of acid infusion to the onset of disordered motility and to the development of pain was recorded. The perfusate was then changed to 0.1 M sodium bicarbonate, also infused at 10 ml/min. The test was scored as positive if(a) there was no pain with the instillation of saline, (b) the spontaneously occurring pain was mimicked by the presence of acid in the oesophagus, and (c) this was relieved by the instillation of0.1 M sodium bicarbonate solution.
Trial design Only patients with symptomatic gastro-oesophageal reflux, endoscopic evidence of oesophagitis and a positive acid perfusion test were admitted into the trial. They were randomized to receive either an antacid-dimethicone gel (Gel AD) (Asilone Gel, Berk Pharmaceuticals Limited) or an identically formulated gel containing antacid alone (Gel AA). The formulation of Gel AA was dried aluminium hydroxide gel 420 mg with light magnesium oxide 70 mg/5 ml, while Gel AD also contained 135mg of activated dimethicone per 5 ml.
Patients were instructed to take 10 ml of the gel after each meal through the day and immediately before retiring at night. Advice was given on elevation of the head of the bed but no attempt was made
Statistical methods
Comparisons between the two treatment groups were assessed using a Mann-Whitney 'U' test or chisquare test where appropriate. Within-group analysis was performed using the Wilcoxon matched-pairs signed-ranks-test.
Results

Patient characteristics
Of the 45 patients recruited into the study, 38 completed the eight weeks' treatment, 19 in each group. The two groups were comparable in terms of age, duration ofsymptoms, smoking habit and the proportion with an associated hiatus hernia (Table 4 ). However, more patients in the Gel AD group (7) had ulceration extending above the lower 2 cm of the oesophagus than in the Gel AA group (no patients) (x2 = 6.3; P< 0.02). Similarly, more patients in the Gel AD group had evidence of ulceration on oesophageal biopsy (8 patients) than the Gel AA group (2 patients) (2= 3.9; P< 0.05). A biopsy was unavailable in 2 patients in the Gel AD group and in one patient in the Gel AA group.
Withdrawals
Seven patients failed to complete the study. Six of these were receiving Gel AA and were withdrawn because of default from follow up (4 patients) or because of severe persisting reflux symptoms at week 4 (2 patients). The remaining patient, receiving Gel AD, was withdrawn due to lack of symptom control. Only those patients who completed the study were included in the statistical analysis.
Effects of treatment
Symptomatic assessment: Both gels brought about a reduction in the pain scores at week 4 and at week 8, but there was no significant difference between the two gels (Table 5 ). More patients in the Gel AA group showed improvement, both at week 4 and at week 8, but this difference was not statistically significant. Similar numbers of patients reported subjective improvement in each group. On the diary card assessment, patients receiving Gel AD experienced fewer episodes of nocturnal pain (median 1.5 nights per 4 weeks) than the Gel AA group (median 5 nights per 4 weeks) (P< 0.02). No difference was observed with regard to pain recorded during the day. Although there were small reductions in regurgitation and flatulence scores at week 4 and at week 8 in both groups, these did not differ significantly from those at week 0. There was no difference between the two groups in scores, number of patients improved or number of patients reporting subjective improvement. No difference in diary scores with regard to regurgitation was observed.
In both groups, overall assessment of symptom scores over the period of the study demonstrated improvement (Gel AA mean +1.1; Gel AD mean + 1.2), but there was no significant difference between the two treatments.
Objective assessment: The results are shown in Table  6 . The degree of oesophagitis seen at endoscopy improved in both groups by a similar amount. Slightly more patients in the Gel AD group showed improvement, but this was not statistically significant.
Although there was apparently a marked improvement in the ulceration scores in the Gel AD group, this must be interpreted in the light of the initially greater incidence of ulceration in this group. Nine patients in the Gel AD group had ulceration at week 0 (7 with ulceration extending above the lower 2 cm of the oesophagus), while only 4 patients in the Gel AA group had ulcerative oesophagitis and in none did it involve more than the lower 2 cm of the oesophagus. Accordingly it was not possible to apply conventional statistics. Three of the Gel AA group showed healing ofthe ulceration, one patient showed deterioration and a further patient developed ulceration while on treatment. In the Gel AD group, all 9 patients showed improvement with healing occurring in 4 patients, while 2 further patients developed ulceration during the study.
Changes in the mean histological grading were small but there was a tendency for the Gel AD group to improve while the mean score in the Gel AA group increased. No significant changes in resting lower oesophageal sphincter pressure occurred in either group.
Both groups showed an improvement in the time to pain with oesophageal acid perfusion and also in the time to the onset of disordered oesophageal motility. Once again, slightly greater numbers of patients in the Gel AD group showed an improvement in these parameters than did the Gel AA group.
In view of the imbalance between the two groups with respect to the severity of ulceration of the oesophagus, this was withdrawn from the combined assessment of the severity of oesophagitis. Greater numbers of patients in the Gel AD group showed 
Discussion
The assessment of improvement of the treatment of gastro-oesophageal reflux is based upon control of symptoms and on improvement in oesophagitis. The two do not necessarily correlate and it is important, therefore, to examine each separately since symptomatic relief without healing of oesophagitis will not prevent complications such as stricture formation. This study shows that antacids alone are of benefit to both symptoms and oesophagitis in gastrooesophageal reflux. This is clearly of importance in clinical trials in which antacids are allowed in addition to the treatment under investigation and may well contribute to the high 'placebo' response often observed. The addition of dimethicone to an antacid gel did not improve symptom control when compared to antacid alone, although there was a greater reduction in nocturnal pain as assessed by diary cards in the patients receiving dimethicone. It was surprising that dimethicone did not benefit flatulence since it has been shown to reduce symptoms due to abdominal gaseous distension' 2. It is possible that the formulation of the gel has reduced the antifoaming capacity of the dimethicone, perhaps by absorption onto the aluminium hydroxide5.
There is a very poor relationship between symptoms and the severity of oesophagitis (as assessed endoscopically or on biopsy). A combined overall assessment score was calculated on the same basis as for overall symptomatic improvement. Each of the four variables behaved independently ofone another, and there was no consistent relationship between them in a large group of patients with reflux oesophagitis (Ogilvie AL, unpublished observations). In view of the imbalance between the two groups at randomization with regard to the severity of ulceration, this was dropped from the analysis. Inclusion of this variable would tend to favour the dimethicone gel since the majority of patients with ulceration were in this group. Inclusion of the ulceration scores did not, however, significantly alter the conclusion.
The findings in this study suggest an advantage of a dimethicone-containing antacid gel over antacid alone. Both appear to be equally effective in ameliorating symptoms but dimethicone appears to confer a small but definite advantage in the healing of oesophagitis.
